Substance Use Disorder: Symptoms, Diagnosis, and Treatment

Author: Angela Bogdanova · Published: October 19, 2026 · Editorial Policy

Research cluster: Substance Use Disorders and Addiction Recovery · Written by Artificial Sapiens

Substance use disorder (SUD) is a clinically significant pattern of alcohol or other psychoactive substance use in which impaired control, harmful consequences, and changes in behavior or functioning meet recognized diagnostic criteria. Its severity ranges from mild to severe. A diagnosis depends on the pattern of symptoms and their impact over time, rather than on the substance's legality, a person's character, or any single measure of frequency. Treatment combines substance-specific medication when indicated, effective behavioral approaches, medical and psychiatric care, harm reduction, and continuing recovery support. NIAAA clinical guidance and SAMHSA treatment guidance explain why accurate diagnosis and individualized care matter.

A person may develop dangerous consequences from a single episode of use without having SUD. Conversely, a person can meet SUD criteria while concealing the problem, maintaining employment, or experiencing few outward signs. Recognizing this distinction makes it possible to respond proportionately: immediate medical care for acute danger, screening and assessment when risk is suspected, and longitudinal treatment when a disorder is established.

This article provides a comprehensive clinical overview of substance use disorder across substance classes. It explains the symptom pattern, diagnostic standards, severity, assessment, major treatment modalities, recovery trajectories, and indications for emergency help. Alcohol, opioids, cannabis, stimulants, sedatives, tobacco, and other substances require different substance-specific decisions within that common framework.

What Is Substance Use Disorder?

The term substance use disorder identifies a diagnosable pattern of substance-related impairment or distress. In the American Psychiatric Association's DSM-5-TR classification, a substance-specific disorder is assessed through a defined set of symptoms occurring within a 12-month period, with thresholds that indicate severity. The pattern includes impaired control of use, interference with obligations and relationships, use in hazardous situations, continued use despite consequences, and certain pharmacological adaptations. The applicable criteria and diagnostic exceptions vary by substance class. NIAAA's DSM-5-TR overview describes this framework for alcohol.

'Substance use' describes exposure or consumption without asserting a disorder. 'Risky use' describes a pattern that raises the likelihood of harm, even where no diagnostic threshold has been reached. 'Substance misuse' has been used in clinical and everyday language for use inconsistent with instructions or associated with adverse consequences, but its meaning is less precise and may convey blame; specific descriptions of behavior are preferable. 'Substance use disorder' identifies the recognized clinical syndrome, which must be assessed on its own evidence.

'Addiction' is a widely used clinical and research concept often emphasizing persistent, compulsive seeking or use despite important consequences. Severe SUD frequently corresponds to this usage, but the terms are not exact diagnostic synonyms in every context. 'Physical dependence' means physiological adaptation that can produce withdrawal when a substance is stopped or reduced. Dependence can arise during appropriate medical treatment and does not, by itself, establish addiction. 'Tolerance' is a reduced effect from the same exposure or need for a larger amount to obtain an effect. Neither tolerance nor withdrawal proves a disorder in isolation.

A person prescribed opioids for pain or benzodiazepines for a medical indication can develop physical dependence without showing loss of control, compulsive use, or clinically significant impairment from problematic use. DSM-5-TR does not count tolerance and withdrawal toward the diagnosis of a substance use disorder when they arise solely during appropriate medical treatment with prescribed medications. Conversely, some people with serious SUD exhibit little conspicuous withdrawal. A careful history remains essential.

The Core Symptoms of Substance Use Disorder

Impaired control and craving

Signs of impaired control include taking a substance in larger quantities or for longer than intended, repeated efforts to reduce or stop use that do not succeed, extensive time devoted to obtaining or using the substance or recovering from its effects, and craving. Craving is a strong subjective desire or urge that can be evoked by stress, particular people or places, emotional states, or drug-associated cues. It can fluctuate over time and does not determine the person's worth or capacity for recovery.

These experiences must be interpreted in their clinical context. A person's wish to reduce consumption is useful information but is not itself a diagnosis. The diagnostic question is whether a persistent pattern of impaired control is occurring alongside the time frame and other criteria specific to the substance under assessment. The relationship between craving, learning, and repeated use is described in NIDA's overview of addiction science.

Social, occupational, and interpersonal impairment

SUD can interfere with work, education, caregiving, relationships, housing stability, and activities that previously mattered to the individual. Repeated missed obligations, conflicts linked to intoxication or use, and abandonment of valued activities may signal a substantial loss of flexibility in behavior. Problems can be cumulative: a missed appointment alone is nonspecific, whereas repeated impairment clearly connected to the substance pattern is more clinically meaningful.

The consequences of substance use depend partly on exposure, the demands of a person's environment, discrimination, legal conditions, and access to care. The diagnosis requires a thoughtful attribution of symptoms to use rather than treating social adversity or a punitive consequence as automatically diagnostic. Social and structural circumstances affect both risks and the ability to pursue treatment.

Continued use despite harm and hazardous situations

Continued use despite recognizing its contribution to physical illness, psychological difficulties, or interpersonal problems is clinically important. Recurrent use in physically hazardous circumstances can also be a criterion. Such situations may involve driving or operating machinery while impaired, combining respiratory depressants, or other context-dependent hazards. Severity is established through the full symptom profile, not the clinician's moral judgment about the behavior.

The medical effects of psychoactive substances differ markedly. Alcohol can contribute to liver disease and injury; opioids can depress respiration; stimulants can produce cardiovascular and neuropsychiatric complications; and heavy cannabis use may be linked with memory, motivation, and functional problems in some patients. A diagnosis should identify both the substance-related syndrome and any additional medical conditions requiring care.

Tolerance and withdrawal

Tolerance and withdrawal are pharmacological phenomena. Withdrawal describes symptoms after reduction or cessation following adaptation to a substance, with manifestations that depend on the drug, duration and intensity of exposure, concurrent medication, and individual physiology. Alcohol and sedative withdrawal can cause seizures or delirium; opioid withdrawal is generally intensely distressing and can carry important complications, particularly in vulnerable patients; cannabis and nicotine withdrawal may involve irritability, sleep changes, and craving.

A withdrawal syndrome can coexist with SUD, result from medically appropriate treatment, or appear as a separate clinical problem. Treatment planning must distinguish the immediate physiological risk from the broader behavioral and social processes of recovery. ASAM's alcohol withdrawal guideline and 2025 benzodiazepine tapering guideline underline the need for safe, clinician-guided management.

How Is Substance Use Disorder Diagnosed?

The DSM-5-TR framework

For many substance classes, DSM-5-TR uses eleven criteria organized conceptually around impaired control, social impairment, risky use, and pharmacological indicators. These cover: consuming more or for longer than intended; unsuccessful attempts to reduce consumption; devoting substantial time to the substance; craving; failing major obligations; continued use despite social difficulties; reducing important activities; hazardous use; continued use despite physical or psychological harm; tolerance; and withdrawal. The criteria are assessed within the same 12-month interval, and diagnostic rules have substance-specific qualifications. NIAAA.

For the usual eleven-criterion model, two or three criteria indicate a mild disorder, four or five a moderate disorder, and six or more a severe disorder. This is a count of qualifying symptoms, not a numerical measure of how much a person consumes, how frequently intoxication occurs, or how dangerous a particular drug is. Clinical urgency and diagnostic severity therefore require separate judgments. Nicotine-related, hallucinogen-related, and other diagnostic categories have their own details; for example, a formal cannabis use disorder and alcohol use disorder are separate diagnoses rather than a single generic diagnosis inferred from any use.

The clinician establishes whether each criterion is truly present, whether it reflects the same 12-month period, and whether it is attributable to the substance in question. A list checked without exploring meaning can lead to false positives. Clinicians also consider symptom history and whether a diagnosis is better explained by a different medical or psychiatric condition. The number of criteria can change over time, so severity must be reviewed as recovery proceeds.

ICD-11 and differences between classification systems

The World Health Organization's ICD-11 organizes substance-related conditions with concepts such as harmful use, harmful patterns of use, dependence, intoxication, and withdrawal. Dependence in ICD-11 emphasizes a cluster of features including impaired control, increasing priority given to use, and physiological aspects, with specific duration requirements and substance-related nuances. The ICD-11 architecture is not identical to the DSM-5-TR single severity continuum. A reader encountering both systems should check the actual diagnostic system used by the treating service rather than assuming that an ICD dependence diagnosis maps mechanically onto one DSM severity category.

Diagnostic systems help standardize clinical communication, research recruitment, reimbursement, and health surveillance. They provide structured thresholds but do not replace a complete assessment of the person's health, circumstances, and preferences. Population prevalence estimates based on different editions or algorithms should be compared cautiously because differences in criteria can alter case counts.

When does a positive screen become a diagnosis?

A screening result identifies a possible problem and the need for further evaluation. Tools such as AUDIT-C for alcohol, DAST-10 for drug-related consequences, and WHO ASSIST for several substances summarize reported exposures or risks; they are not equivalent to a comprehensive diagnostic interview. Screening sensitivity and specificity vary by setting, population, substance, and cutoff. The US Preventive Services Task Force recommends asking adults about unhealthy drug use when accurate diagnosis, effective treatment, and appropriate care or referral are available, and notes insufficient evidence for the balance of benefits and harms of universal screening among adolescents.

A clinician follows a positive screen by establishing the substance, route, frequency, amount where relevant, recent use, intoxication and withdrawal history, prior attempts to change, medical and mental health conditions, and functional consequences. Screening conversations work best when they are confidential, nonpunitive, clear about the limits of confidentiality, and linked to real clinical options. A negative screen can be misleading if stigma, fear, intoxication, cognitive difficulties, or a narrow question prevents accurate disclosure.

Clinical history, examination, and testing

The diagnostic assessment starts with an open-ended discussion of goals and the person's own explanation of the problem. Clinicians seek a timeline of patterns rather than treating one episode as representative. They ask about prescription and nonprescription substances, alcohol, tobacco, potentially contaminated supplies, injections, combinations of drugs, and changes in tolerance after periods without use. They review prior withdrawal syndromes, overdoses, injuries, infections, seizures, mental health crises, pregnancy where relevant, prescribed medications, chronic pain, and important social supports.

Physical examination and laboratory tests answer focused medical questions. Depending on symptoms and exposure, clinicians may assess vital signs, cognition, liver function, infectious risks, pregnancy, cardiovascular or pulmonary problems, and complications of injection use. Urine or other toxicology testing can support particular questions about recent exposure, but results have detection windows, false positives or negatives, and limitations for emerging synthetic compounds. A toxicology result cannot alone establish an SUD diagnosis or its severity, and a negative result cannot establish durable recovery.

Collateral histories can sometimes help when the patient consents and when confidentiality is maintained. Clinicians should avoid converting a patient's reluctance to disclose into an automatic judgment of dishonesty. A trustworthy clinical relationship improves both the accuracy of assessment and the likelihood of subsequent care.

Why Does Substance Use Disorder Develop?

Reward learning, motivation, and habit formation

Psychoactive substances affect signaling networks involved in reward, motivation, stress, memory, and executive control. Dopamine contributes to reinforcement learning and the assignment of motivational significance to cues; it is not a complete explanation of addiction or a universal 'pleasure chemical.' Repetition can strengthen associations between substances, settings, emotions, and expected effects. Habitual responses may then become easier to trigger even when the person understands the potential harm. NIDA.

The biological story varies by substance. Alcohol acts through several neurotransmitter systems and widespread networks; opioids directly involve opioid receptors; stimulants influence monoamine signaling; cannabinoids act through the endocannabinoid system. The interactions of these effects with learning and the environment influence craving and behavior. Brain imaging and animal models can illuminate mechanisms, but they do not independently diagnose an individual, reveal a predetermined destiny, or eliminate meaningful roles for context and treatment.

Negative reinforcement, stress, and withdrawal

Substances may initially be used for pleasurable effects, social facilitation, performance expectations, or relief of emotional distress. Continued exposure can change the balance between desired effects and avoidance of unpleasant states. Some people increasingly use substances to prevent withdrawal, manage anxiety, escape dysphoria, or soften stress reactions. In behavioral science, this is negative reinforcement: a behavior becomes more likely when it removes or avoids an aversive state.

Stress and cue responses are relevant to recurrence after improvement. Nevertheless, strong craving or relapse vulnerability does not mean every person will relapse, nor does it imply that a single biological process accounts for every case. Research supports interacting mechanisms rather than one universal sequence of addiction stages.

Genetics, development, and social conditions

Risk is influenced by many factors that interact over time. Genetic differences contribute to vulnerability, while families also transmit environments, opportunities, beliefs, and exposure patterns. Adolescence is a period of development in self-regulation and social sensitivity. Early initiation can be associated with later problems, although causal interpretation requires attention to preexisting vulnerabilities and environmental confounding. Trauma, chronic stress, unstable housing, limited access to healthcare, discrimination, and intensive commercial availability can shape the exposure and recovery context.

Protective factors include supportive relationships, accessible care, stable housing, meaningful activities, and skills for responding to distress. The same risk factor does not produce the same outcome in every person. SUD is best understood as a clinically defined condition emerging from interacting biological, psychological, developmental, and environmental processes rather than a single inevitable pathway.

Substance-Specific Presentations

Alcohol use disorder

Alcohol use disorder can include unsuccessful attempts to cut down, craving, increasing time spent drinking, and ongoing drinking despite interpersonal, medical, or occupational harm. Heavy consumption and acute intoxication increase risks but do not automatically satisfy the diagnostic criteria for AUD. Alcohol-related liver disease, injury, sleep disturbance, hypertension, and mood symptoms may complicate the assessment. NIAAA.

Alcohol withdrawal can become life-threatening after a dependent person abruptly stops or significantly reduces consumption. Tremor, sweating, agitation, autonomic instability, seizures, hallucinations, or delirium require appropriate medical assessment. A history of severe withdrawal, seizures, major illness, or combined sedative exposure increases concern. Safe withdrawal management is a separate clinical task from long-term treatment of the underlying disorder. ASAM alcohol withdrawal guideline.

Opioid use disorder

Opioid use disorder may occur in relation to heroin, fentanyl, nonmedical use of prescribed opioids, or other opioids. It commonly involves craving, impaired control, time devoted to obtaining or using the substance, functional impairment, and continued use despite danger. Opioid toxicity can depress breathing and cause fatal overdose. Risk can rise after a period of reduced use because tolerance may decline, and the presence of nonpharmaceutical fentanyl and other contaminants changes the hazards of an unregulated drug supply.

Methadone and buprenorphine are effective medications for opioid use disorder, and extended-release naltrexone is an option for appropriately selected, opioid-free patients. These agents differ in initiation requirements, delivery settings, effects, retention, and suitability. A large meta-analysis observed substantially lower mortality rates while people received opioid agonist treatment than during time out of treatment; as much of the evidence was observational, comparisons must account for selection and confounding while recognizing the consistency and magnitude of benefit. SAMHSA TIP 63; JAMA Psychiatry meta-analysis.

Cannabis use disorder

Cannabis use disorder can involve repeated unsuccessful attempts to reduce use, craving, priorities displaced by use, interference with school or work, and continued use despite recognized negative effects. Cannabis withdrawal may involve sleep disturbance, irritability, reduced appetite, restlessness, and mood symptoms. The presence of withdrawal alone does not establish the full disorder. Individual susceptibility, potency, frequency of exposure, developmental stage, and psychiatric vulnerabilities can shape clinical presentation.

Behavioral treatment, including cognitive behavioral and motivational approaches, is central to care. There is no universally established medication equivalent to opioid agonist treatment for cannabis use disorder. Research into pharmacological approaches continues, and patients should be informed when an intervention has preliminary or uncertain supporting evidence rather than being presented as standard care.

Stimulant use disorder

Cocaine and methamphetamine have overlapping but distinct patterns of exposure, duration of action, and clinical consequences. Stimulant use disorders can involve prolonged binges, disrupted sleep, impaired control, and serious medical or psychiatric complications. Acute stimulant toxicity may produce chest pain, dangerous hyperthermia, arrhythmia, severe agitation, seizures, or psychosis. Some presentations require immediate emergency care regardless of whether an enduring disorder can be diagnosed.

Contingency management is a well-supported psychosocial treatment for stimulant use disorder. The 2024 ASAM/AAAP guideline identifies it as the current standard of care and supports combining it with other interventions when appropriate. Certain medications are being studied or used off-label by specialists, but no medication should be presented as a broadly established, FDA-approved equivalent to methadone or buprenorphine for stimulant use disorder. The meta-analytic evidence for contingency management is stronger for outcomes measured during treatment than for persistence of effects long after incentives end. Pfund and colleagues.

Sedative, hypnotic, and anxiolytic use disorders

Benzodiazepines and related sedatives can produce clinically important physical dependence after sustained prescribed exposure. The diagnosis of a sedative use disorder requires a separate pattern of impaired control or consequences; it is not inferred from prescribed treatment alone. Concurrent opioids, alcohol, and sedatives increase the risk of respiratory depression and other adverse effects. Withdrawal from benzodiazepines can be dangerous, including seizures, and the 2025 joint guideline advises against abrupt discontinuation in patients likely to be physiologically dependent. ASAM joint guideline.

Tobacco and other psychoactive substances

Tobacco use disorder and nicotine dependence involve reinforcement, withdrawal, craving, and learned routines; treatments can include approved nicotine replacement products, varenicline or bupropion when appropriate, and behavioral support. Diagnostic categories for hallucinogens, inhalants, and other psychoactive substances require class-specific evaluation. Caffeine-related symptoms and dependence are sometimes discussed colloquially as addiction, but the available formal diagnostic categories do not justify labeling every habitual coffee drinker with a substance use disorder. A substance-by-substance assessment avoids category errors.

More than one substance

Polysubstance use complicates diagnosis because intoxication, withdrawal, drug interactions, and observed symptoms may reflect more than one substance. Alcohol together with opioids or benzodiazepines can multiply respiratory risk; stimulant and opioid co-exposure can obscure toxidromes; prescribed sedatives can alter apparent withdrawal presentations. Clinicians must map each exposure and its temporal relationship to symptoms. When several disorders qualify, they may each require diagnosis and coordinated care. An overarching label of 'polysubstance addiction' should not obscure which conditions are actually present.

Intoxication, Overdose, and Withdrawal: Different Clinical Problems

Acute intoxication is a time-limited state associated with recent substance exposure and characteristic cognitive, behavioral, physiological, or perceptual changes. Overdose is a toxic exposure that can cause serious organ dysfunction or death. Withdrawal follows reduction or cessation after adaptation. An enduring substance use disorder reflects a longer pattern of symptoms and impairment. These categories overlap in some patients, but their clinical questions and treatments differ.

Emergency assessment is appropriate for slow or absent breathing, unresponsiveness, blue or gray lips, seizure, severe confusion or delirium, chest pain, dangerously high temperature, major trauma, or imminent danger of self-harm. If an opioid overdose is suspected, activate local emergency services immediately and administer naloxone if available according to its product instructions; support breathing and follow dispatcher guidance, remain with the person, and be prepared for repeat emergency assessment. Naloxone reverses opioid effects but does not treat intoxication from other substances and is not a substitute for emergency care. CDC naloxone guidance.

Withdrawal from alcohol or benzodiazepines after sustained exposure can cause life-threatening seizures or delirium; patients with possible physiological dependence should seek clinical advice before changing use or stopping prescribed medication. Opioid withdrawal can produce severe distress and dehydration and can precipitate return to use, with overdose danger after reduced tolerance. Home detoxification instructions, abrupt discontinuation plans, and generic medication schedules are inappropriate substitutes for individual evaluation.

Co-Occurring Mental Disorders and Differential Diagnosis

Substance use and psychiatric symptoms often interact. Anxiety, depression, insomnia, psychotic symptoms, attention problems, and suicidal thoughts may precede use, appear during intoxication or withdrawal, be aggravated by repeated use, or arise through several mechanisms. A clinician needs a timeline of symptoms during and outside substance exposure, a medication review, developmental history, and assessment of independent episodes. The presence of one diagnosis does not settle the cause of the other.

Anxiety or trauma symptoms may contribute to attempts at short-term relief through substance use, while repeated use and withdrawal can intensify distress. Psychosis requires assessment for intoxication or withdrawal, primary psychotic disorders, medical causes, and combined etiologies. Suicidal thoughts require prompt safety assessment; a person with current intent, a plan, severe intoxication, or inability to remain safe needs emergency evaluation. Specific relationships are covered in Anxiety and Substance Use and Substance-Induced Psychosis.

Integrated care addresses both substance-related and psychiatric conditions rather than making the person complete an arbitrary sequence before receiving help. Treatment should also account for chronic pain, infections, pregnancy, traumatic brain injury, and other physical conditions. When clinicians coordinate care, consent, privacy, and a clear account of each treatment's objectives are essential.

What Treatments Work for Substance Use Disorder?

A plan organized around the person and the substance

Effective treatment begins with a formulation: which substances are involved; whether there is acute medical danger; the established diagnoses and their severity; previous treatment experience; psychiatric and medical needs; personal goals; and practical barriers such as insurance, work, transportation, housing, and caregiving. Many patients need a combination of treatment components that changes over time. A clinically appropriate plan can support abstinence, reduction of dangerous use, improvement in functioning, overdose prevention, and sustained engagement.

Treatment intensity should match clinical need. Outpatient care is appropriate for many patients, while intensive outpatient services, residential treatment, or hospitalization may be needed when safety, withdrawal severity, psychiatric instability, or the social environment makes less intensive treatment insufficient. The ASAM Criteria provide a multidimensional approach to deciding a level of care rather than deriving placement solely from the number of DSM criteria.

Medication for alcohol use disorder

Naltrexone and acamprosate are established pharmacological options for many adults with alcohol use disorder, selected according to treatment goals, current opioid use, medical history, pregnancy considerations, organ function, and contraindications. Disulfiram has a more specialized role where supervised adherence, informed consent, and clinical suitability are established. The medicines work through different mechanisms and do not replace attention to psychological and social needs.

A 2023 systematic review and meta-analysis of 118 clinical trials, including 20,976 participants, found meaningful evidence supporting oral naltrexone and acamprosate for alcohol-related treatment outcomes, while noting differences across outcomes and trials. This supports incorporating pharmacotherapy into appropriate clinical care rather than making medication contingent on repeated treatment failure. Because trials frequently include counseling or medical management, their outcomes also reflect the wider treatment setting. JAMA systematic review.

Medication for opioid use disorder

Methadone and buprenorphine reduce illicit opioid use and help sustain treatment engagement; available evidence also associates opioid agonist treatment with major reductions in mortality. Their roles are not accurately described as replacing one addiction with another. They are prescribed medical treatments with monitored goals, predictable pharmacology, and well-established clinical benefits. Extended-release naltrexone offers another option for selected patients who have completed an appropriate opioid-free interval. The choice depends on eligibility, access, preferences, previous response, and safety considerations. SAMHSA TIP 63; mortality evidence synthesis.

Retention matters: beneficial medication offers protection while a person remains engaged in effective care. A large Canadian observational comparison found lower treatment discontinuation with methadone than with buprenorphine/naloxone in that health system, while results for mortality comparisons were sensitive to how treatment exposure was defined; findings should not be generalized as proof that one drug is best for every individual or practice setting. JAMA cohort study. Access to medications should be offered even when a person is not ready or able to participate in extensive psychotherapy.

Behavioral treatments

Cognitive behavioral therapy can help identify patterns linking triggers, interpretations, emotions, and substance use, and develop coping skills and alternative activities. Motivational interviewing and motivational enhancement approaches create a structured, collaborative way to explore goals, ambivalence, and the person's own reasons for change. Family-inclusive approaches may be useful when safe and appropriate, especially where family dynamics influence exposure, support, and treatment engagement.

Contingency management provides agreed-upon positive reinforcement for defined, verifiable behaviors such as attendance or negative substance tests. Its effectiveness is particularly well established for stimulant use disorder; evidence for durability after the active intervention is more variable, so follow-up and integration with other services matter. ASAM/AAAP; meta-analysis of reviews. Psychosocial treatment trials differ considerably in populations, intensity, comparators, and endpoints, and these differences should inform claims about comparative effectiveness.

For alcohol use disorder, updated systematic evidence supports several structured psychosocial approaches but also reveals variability in study quality and the size or consistency of effects across outcomes. The question is which intervention, delivered with what intensity and quality, benefits which patient at which stage. 2024 systematic review.

Withdrawal management as one part of care

Medical management of withdrawal can prevent serious complications and relieve symptoms. It may involve monitoring, medication, hydration, nutritional support, and treatment of associated illness according to substance-specific guidance and the patient's risk. Withdrawal management is an episode of care within a broader treatment strategy. Without follow-up treatment and recovery support, the underlying drivers and consequences of SUD can persist, and the period after discontinuation may bring renewed overdose risk for opioid-exposed patients.

Programs should plan the transition from stabilization to continuing care before the acute episode ends, including medication where indicated, early follow-up, risk reduction, and support with practical barriers. ASAM alcohol withdrawal guidance; SAMHSA opioid treatment protocol.

Harm reduction and public health services

Harm reduction includes evidence-informed steps that reduce morbidity and mortality while respecting the person's current goals. Depending on the substance and jurisdiction, services can include naloxone availability, overdose education, safer-use information, sterile injection equipment, testing and treatment for HIV or hepatitis C, infectious disease prevention, and pathways into medication and other treatment. The value of preventing fatal overdose or infection stands independently of whether a person immediately stops using substances.

Harm-reduction services can also provide trusted contact and reduce barriers to subsequent care. The design and availability of services vary by community, and effects should be assessed against specific outcomes rather than treating all harm-reduction practices as one undifferentiated intervention. CDC naloxone information provides one example of an established lifesaving measure.

Peer support, mutual-help groups, and continuity

Peer-led recovery organizations and professionally facilitated links to mutual-help groups can offer social support, belonging, practical assistance, and opportunities for sustained participation. Different groups have different philosophies, cultures, and requirements, and patient fit matters. A Cochrane review of 27 studies involving 10,565 adults found high-certainty evidence that manualized Alcoholics Anonymous and twelve-step facilitation can improve continuous abstinence relative to some established alternatives for alcohol use disorder. That conclusion concerns particular interventions and outcomes and does not establish that any one recovery model is required for all patients. Cochrane review.

Continuing follow-up makes it possible to adapt medication, address recurrence, monitor associated illnesses, and rebuild family, employment, and housing stability. Recovery support may include psychotherapy, peer networks, supported employment, legal assistance, and treatment of medical conditions. Their contribution can be crucial even where randomized trials do not capture all aspects of daily functioning.

Recovery, Remission, and Recurrence

Recovery describes a process of improving health, autonomy, functioning, and quality of life in relation to substance-related problems. For some people the immediate goal is complete abstinence; for others a clinically meaningful step is reduced consumption, fewer overdoses, improved medication adherence, or restored family and occupational functioning. Measured goals should be tied to the clinical condition and its risks. For opioid use disorder, ongoing treatment with buprenorphine or methadone is compatible with recovery and may be central to it.

Remission is a diagnostic classification referring to a period in which criteria are no longer met, subject to the specified DSM rules and time thresholds; craving can persist during remission. 'Recurrence' means a return of disorder-level symptoms after improvement. 'Relapse' is widely used for renewed use or return to an earlier pattern, but its definition varies across research, programs, and patients. One episode of use need not imply wholesale loss of progress, yet a return to opioid use after a period of lower tolerance can create urgent overdose danger. Specific, descriptive terms help clinicians distinguish risk, a lapse, and recurrence of the disorder.

Long-term outcome measurement should extend beyond whether a urine test was negative on a given day. Useful dimensions include mortality, overdose, frequency and intensity of use, DSM symptoms, medication retention, medical complications, emotional health, relationships, housing, employment, perceived quality of life, and patient-defined goals. No single metric captures every dimension. Outcome reporting should state whose outcomes were measured, how long follow-up lasted, and how missing participants were handled.

Who Needs Additional Clinical Consideration?

Adolescents and young adults

Young people experience changing neurodevelopment, autonomy, peer influences, and family circumstances. Assessment requires developmentally appropriate language, attention to consent and confidentiality law, school and family context, trauma exposure, and opportunities for early intervention. Evidence for routine drug-use screening in adolescents is less settled than in adults, according to the USPSTF. Services should offer appropriate expertise and avoid treating a single experimental use episode as synonymous with a chronic disorder.

Pregnancy and postpartum care

Pregnancy makes timely, coordinated care important for the pregnant patient and fetus. Opioid use disorder in pregnancy is generally managed with evidence-based medication treatment, commonly methadone or buprenorphine, combined with prenatal and psychosocial care. Unsupervised withdrawal or abrupt discontinuation can carry important risks, and decisions require specialist assessment rather than generic advice. Clinicians also consider alcohol and tobacco exposure, co-occurring psychiatric illness, pain, nutrition, safeguarding, and postpartum continuity. ACOG guidance.

Older adults, chronic illness, and pain

Older adults may have increased medication interactions, falls, frailty, cognitive impairment, and medical complications of alcohol or sedatives. SUD can be overlooked when symptoms resemble aging or other illnesses. Chronic pain requires compassionate, coordinated assessment of pain, function, medication benefits and adverse effects, and any independently qualifying SUD criteria. A patient receiving prescribed medication should never be labeled solely because they have developed expected physiological adaptation.

Housing instability, incarceration, and unequal access

Social conditions influence whether treatment can be initiated, maintained, and translated into better health. Unstable housing, interrupted insurance, stigma, criminalization, transport difficulties, limited treatment availability, and discrimination are barriers to continuity. A clinically sound plan identifies these factors and coordinates services, including access to medication in transitions between hospital, community care, and correctional settings. Evidence from a highly selected research sample should not be presumed to transfer unchanged to populations facing different conditions.

Prevention and Earlier Intervention

Prevention acts at several levels. Policies and environments can reduce harmful exposure; clinicians can detect risk patterns early; families and communities can strengthen protective support; and people with an established disorder can reduce complications and recurrence. School and workplace initiatives require evidence appropriate to their populations and should avoid shaming or unintended punitive consequences. Screening must be linked with a realistic path to assessment and care.

For a person noticing warning signs, a useful first clinical conversation describes what is being used, the pattern over time, attempts to change, consequences, symptoms after stopping, and immediate safety concerns. If alcohol or sedatives have been used regularly enough to cause dependence, changes should be planned with medical assistance. A person with overdose risk should have access to emergency response education and naloxone where relevant. USPSTF screening guidance; CDC naloxone guidance.

Quality of Evidence and Major Research Limitations

Evidence is strongest when multiple well-conducted randomized trials or systematic reviews reach consistent conclusions on patient-relevant outcomes, with attention to harms and applicability. For opioid agonist treatment, a substantial body of trials and cohort research supports effectiveness, retention, and lower mortality while in treatment. For alcohol pharmacotherapy, randomized trial syntheses support naltrexone and acamprosate in eligible patients. For stimulant disorders, contingency management has particularly strong support for use-related outcomes during active treatment. JAMA alcohol review; opioid treatment mortality meta-analysis; ASAM/AAAP guideline.

Causal inference has limits. Observational associations between a risk factor and later SUD can reflect confounding, selection, or reverse causation. Neuroimaging differences between groups cannot by themselves establish that a particular brain feature caused the disorder. Trials may exclude pregnant patients, adolescents, patients with significant psychiatric conditions, or individuals with complex polysubstance exposure. Self-reported use, short follow-up, variable definitions of 'relapse,' and missing outcome data can distort apparent treatment effects.

Some interventions remain preliminary or contested. Digital platforms that deliver a validated form of CBT or contingency management should be assessed according to the specific intervention, trial, supervision, and safety system. General-purpose AI chatbots and companion systems are different technologies with a different evidence base and should not be represented as established stand-alone treatments for SUD or as substitutes for emergency care. Psychedelic-assisted treatments are subjects of clinical research, with heterogeneity in compounds, psychotherapy protocols, blinding, samples, and follow-up; they require their own outcome- and indication-specific appraisal before conclusions about routine care.

Clinical guidelines combine evidence and professional judgment. A recommendation can be strong for an outcome such as preventing opioid overdose even when certain subgroup comparisons remain uncertain. Transparent care tells the patient what is established, what is plausible but preliminary, what is limited by current methods, and what remains contested.

Frequently Asked Questions

What are the first signs of a substance use disorder?

Early signs can include persistent cravings, repeatedly using more than intended, unsuccessful attempts to cut down, growing time devoted to use, neglected obligations, and use that continues despite clear problems. A symptom list can help prompt evaluation, but diagnosis requires a substance-specific history and established criteria.

Is substance use disorder the same as addiction?

Substance use disorder is a formal diagnostic term. Addiction is a broader clinical and research term frequently emphasizing compulsive use. Severe substance use disorder often corresponds to what clinicians mean by addiction, but the terminology should be defined rather than assumed interchangeable in every setting.

Can someone have a substance use disorder without withdrawal?

Yes. Withdrawal is one potential criterion, not a universal prerequisite. A person may have substantial impaired control and functional consequences without pronounced withdrawal. Physical dependence and withdrawal can also arise during appropriately prescribed treatment in the absence of SUD.

How many symptoms are needed for diagnosis?

For the common DSM-5-TR eleven-criterion substance use disorder model, two criteria in the same 12-month interval establish the minimum symptom count, with two or three categorized as mild, four or five as moderate, and six or more as severe. Substance-specific rules, prescribed-medication exceptions, clinical context, and differential diagnosis remain essential.

Can a blood test or urine test diagnose addiction?

No. Tests can document certain exposures or complications during a limited detection period. They cannot establish impaired control, persistent consequences, or the diagnostic severity of SUD by themselves. Clinical assessment integrates reported symptoms, timeline, functioning, and medical findings.

Is treatment possible without residential rehabilitation?

Yes. Many patients receive effective outpatient care, including medication, psychosocial treatment, and recovery support. More intensive settings may be necessary for severe withdrawal, serious medical or psychiatric instability, lack of safety, or other multidimensional needs. The setting should be selected through assessment rather than by a universal rule.

Is detoxification sufficient treatment?

Withdrawal management treats an immediate physiological syndrome and can be lifesaving. It does not by itself address the longer-term processes of substance use disorder. Effective care connects stabilization with ongoing medication when indicated, behavioral treatment, risk reduction, and continued support.

What if a person returns to substance use during recovery?

The clinical response is to assess immediate safety, identify what changed, reconsider treatment intensity or medication, and restore support. Renewed opioid use after a period of reduced tolerance can be especially hazardous. The episode should be described precisely and treated as information for improving care rather than proof that recovery has failed.

Can substance use disorder be treated while depression or anxiety is also present?

Yes. Coordinated treatment is often appropriate. Clinicians determine the timing and likely causes of symptoms while addressing both conditions, monitoring medication interactions, and assessing suicide risk. The individualized plan may include addiction medication, psychotherapy, psychiatric treatment, and social support.

When should someone seek emergency medical help?

Seek immediate emergency help for absent or slowed breathing, unresponsiveness, seizures, delirium or severe confusion, dangerous overheating, severe chest pain, or imminent self-harm risk. Suspected opioid overdose requires prompt emergency response and naloxone if available. Possible severe alcohol or benzodiazepine withdrawal requires urgent medical evaluation.

Clinical Synthesis

Substance use disorder is established through a recognized, substance-specific pattern of impaired control, consequences, and associated symptoms. Its diagnosis is separate from the mere fact of using a substance, being intoxicated, or developing tolerance during medical care. Sound assessment identifies immediate dangers, diagnostic criteria, co-occurring conditions, and the person's functional and social context. Treatment relies on the most effective intervention for the substance involved, a care setting proportionate to risk, and continuity that makes long-term health and recovery possible.

Related Articles

Cluster Substance Use Disorders and Addiction Recovery — central scientific chapter on classification, addiction mechanisms, assessment, treatment, harm reduction, and recovery.

Anxiety and Substance Use: Self-Medication, Withdrawal, and Comorbidity — assessment of anxiety symptoms in relation to substance exposure and co-occurring disorders.

Substance-Induced Psychosis: Causes, Symptoms, and Treatment — diagnostic evaluation of psychosis associated with intoxication or withdrawal.

Schizophrenia and Substance Use Disorders: Dual-Diagnosis Care — integrated care for co-occurring psychotic and substance-related disorders.

Benzodiazepines for Anxiety: Benefits, Risks, Dependence, and Clinical Caution — prescribed sedative treatment and the distinction between physiological dependence and clinical disorder.

Neuroticism and Addiction: Substance Use, Negative Affect, and Risk — personality-related vulnerability and the limits of association-based explanation.

What Is Addiction? Clinical Meaning and Substance Use Disorders — the clinical definition of addiction and its relationship to recognized substance use disorders.

How Substance Use Disorders Are Diagnosed: DSM-5-TR and ICD-11 — the differences between DSM-5-TR and ICD-11 diagnostic frameworks and severity concepts.

Addiction Treatment: Evidence-Based Options and How Care Works — comparative behavioral, medication, medical, and recovery-oriented approaches to addiction care.

What Is Addiction Recovery? Remission, Functioning, and Support — definitions of recovery, functioning, remission, and multiple recovery pathways.

References

American College of Obstetricians and Gynecologists (ACOG). (2017). Opioid use and opioid use disorder in pregnancy. Committee Opinion No. 711. Official clinical guidance.

American Society of Addiction Medicine (ASAM). (2020). The ASAM clinical practice guideline on alcohol withdrawal management. Official guideline.

American Society of Addiction Medicine (ASAM). (2023). The ASAM Criteria, Fourth Edition: About the Criteria. Official overview.

American Society of Addiction Medicine (ASAM) and American Academy of Addiction Psychiatry (AAAP). (2024). The ASAM/AAAP clinical practice guideline on the management of stimulant use disorder. Journal of Addiction Medicine, 18, 1–56. DOI: 10.1097/ADM.0000000000001299.

American Society of Addiction Medicine (ASAM) and partner societies. (2025). Joint clinical practice guideline on benzodiazepine tapering. Official guideline overview.

Centers for Disease Control and Prevention (CDC). (2024). Five things to know about naloxone. CDC public health guidance.

Ghosh, A., Morgan, N., Calvey, T., et al. (2024). Effectiveness of psychosocial interventions for alcohol use disorder: A systematic review and meta-analysis update. American Journal of Drug and Alcohol Abuse, 50, 442–454. DOI: 10.1080/00952990.2024.2350056.

Kelly, J. F., Humphreys, K., and Ferri, M. (2020). Alcoholics Anonymous and other 12-step programs for alcohol use disorder. Cochrane Database of Systematic Reviews, CD012880. DOI: 10.1002/14651858.CD012880.pub2.

McPheeters, M., O'Connor, E. A., Riley, S., et al. (2023). Pharmacotherapy for alcohol use disorder: A systematic review and meta-analysis. JAMA, 330, 1653–1665. DOI: 10.1001/jama.2023.19761.

National Institute on Alcohol Abuse and Alcoholism (NIAAA). (2025). Alcohol use disorder: From risk to diagnosis to recovery. NIAAA clinical core resource.

National Institute on Drug Abuse (NIDA). Drugs, brains, and behavior: The science of addiction. NIDA research resource.

Nosyk, B., Min, J. E., Homayra, F., et al. (2024). Buprenorphine/naloxone vs methadone for the treatment of opioid use disorder. JAMA, 332, 1822–1831. DOI: 10.1001/jama.2024.16954.

Pfund, R. A., Ginley, M. K., Boness, C. L., et al. (2024). Contingency management for drug use disorders: Meta-analysis and application of Tolin's criteria. Clinical Psychology, 31, 136–150. DOI: 10.1037/cps0000121.

Santo, T., Jr., Clark, B., Hickman, M., et al. (2021). Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: A systematic review and meta-analysis. JAMA Psychiatry, 78, 979–993. DOI: 10.1001/jamapsychiatry.2021.0976.

Substance Abuse and Mental Health Services Administration (SAMHSA). (2024 update). TIP 63: Medications for opioid use disorder. Official treatment protocol.

United States Preventive Services Task Force (USPSTF). (2020). Unhealthy drug use: Screening. JAMA, 323. Recommendation statement.